promyelocytic

promyelocytic

pertaining to a promyelocyte.
References in periodicals archive ?
The rare but difficult-to-treat acute promyelocytic leukemia (APL) proved the first cancer to succumb to a retinoic acid.
Tamibarotene is being tested in a double-blind, placebo-controlled, international Phase 2b clinical trial in patients with non-small-cell lung cancer, and is in a Phase 2 clinical trial as a treatment for acute promyelocytic leukemia (APL).
Treatment of acute promyelocytic leukemia (APL) with retinoic acid (RA) is the first model of differentiation therapy, and it has proven extremely successful in inducing clinical remission (CR) in most patients.
In vivo, TLK58747 demonstrated significant antitumor activity both orally and parenterally against a wide variety of human tumor types, including breast, pancreatic, prostate, and colorectal carcinomas, as well as glioma and promyelocytic leukemia.
Nippon Shinyaku) has launched TRISENOX(R) (arsenic trioxide) in Japan after receiving pricing approval from the Japanese Ministry of Health to market the drug for patients with relapsed or refractory acute promyelocytic leukemia (APL).
Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway.
It was set up by Melissa Ginns and Ian Mustard following the loss of Ian's 16-year-old daughter Abbie from acute promyelocytic leukaemia in 2013.
EGCG, EA, and RA dose-dependently inhibited the growth of human HL-60 promyelocytic leukemia cells, exerted strong free radical scavenging potential, and significantly imbalanced nuclear deoxyribonucleoside triphosphate (dNTP) concentrations without distinctly affecting the protein levels of RR subunits (R1, R2, p53R2).
TRISENOX, for treating relapsed/refractory acute promyelocytic leukemia, was purchased from Cell Therapeutics by Cephalon, Inc.
Acute promyelocytic leukemia (APL) is characterized by fusion of the promyelocytic leukemia (PML) and retinoic acid receptor alpha (RARA) genes, leading to expression of the aberrant PML-RARA protein.
Jillella's proposal entitled "A Simple Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL)" will be funded over the next five years.